Clinical Trial Update: Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS [Phase 2]

View source ↗

Summary

Phase 2, open-label, single-arm study evaluating BST-236 in adults with relapsed/refractory AML or higher-risk MDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• BST-236

Snippet

Sponsor: BioSight Ltd. | Conditions: AML, Adult, MDS | Phase 2 | Status: UNKNOWN